News | Artificial Intelligence | December 04, 2018

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI

Company will be working with U.K institutions to advance development and adoption of artificial intelligence in radiotherapy treatment planning and diagnostic nuclear medicine

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI

December 4, 2018 — Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI) consortium receiving £50M in new funding from the U.K. government. The funding is part of the government’s drive to expedite the development and adoption of AI in healthcare and the National Health System (NHS).

Mirada developed the first deep learning applications for radiotherapy planning to receive regulatory clearance for clinical use in both Europe and the U.S. The company will bring its expertise and practical experience to projects hosted by Kings College London and the University of Oxford, two of the five centers funded through Wave 2 of the Industrial Strategy Challenge Fund’s ‘Data to Early Diagnosis and Precision Medicine’initiative.

Mirada will be partnering with the London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, led by Kings College London, and will be working closely with Guys & St Thomas hospital. Mirada will be building on its success in commercializing its DLCExpert radiation therapy planning application to deliver the potential of AI to the NHS and demonstrate how advanced medical imaging and deep learning technologies can be used to improve patient care.    

Mirada will also partner with the University of Oxford’s NCIMI (National Consortium of Intelligent Medical Imaging) to investigate the role that AI and deep learning can play in diagnostic nuclear medicine. The company will be building on its established partnership with the Alliance Medical Group and the NHS positron emission tomography (PET) scanning program, where Mirada software is already used to read more than half of the PET/CT (computed tomography) scans in England & Wales.

These initiatives will improve the efficiency of cancer detection and diagnosis, leading to faster cancer treatment delivery, cost reductions for the NHS and improved patient outcomes.

Centre Director Professor Reza Razavi from King’s College London said: “The centre will provide a fantastic opportunity to transform 12 different patient pathways by using advanced imaging and AI and help make the products that will substantially improve the experience for our patients and their clinical outcomes. It will also allow us to better utilize the resources within the NHS. This builds on a great ongoing partnership between our researchers, clinicians and industry colleagues that will help put the UK at the forefront of developing and applying new technologies to improve healthcare.”

For more information: www.mirada-medical.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning

The Siemens Somatom Go.Sim computed tomography (CT) system for dedicated radiation therapy planning. Image courtesy of Siemens Healthineers.

News | Computed Tomography (CT) | September 15, 2019
Siemens Healthineers debuted two computed tomography (CT) systems dedicated to radiation therapy (RT) planning at the...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
3D Systems Earns Additional FDA Clearance for D2P Medical 3-D Printing Software

3D Systems’ D2P FDA-cleared software allows clinicians to 3-D-print diagnostic patient-specific anatomic models. Image courtesy of 3D Systems.

Technology | Medical 3-D Printing | September 12, 2019
3D Systems has received additional U.S. Food and Drug Administration (FDA) 510(k) clearance for its D2P software...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...